N/A N=41 Randomized Double-blind Treatment

Tobacco Treatment in the Context of Lung Cancer Screening

Smoking Cessation

Bottom Line

View on ClinicalTrials.gov: NCT03927989 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2024

Primary outcome: Primary: End of Treatment Abstinence Rates — 3; 0 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Text messaging plus nicotine replacement therapy (Behavioral); Standard Care at Lung Cancer Screening (Other)
Age: Adult, Older Adult · 55+ yrs
Sex: All
Sponsor: Medical University of South Carolina
Primary completion: Oct 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY End of Treatment Abstinence Rates	3; 0	—
SECONDARY End of Study Abstinence Rates	1; 0	—

Summary

The proposed study will test a medication plus text messaging intervention specifically designed for lung cancer screening patients. Half of the patients will receive standard of care, and half will receive the treatment intervention.

Eligibility Criteria

Inclusion:

55 years or older
30 pack year history of smoking
current smoker (defined as breath carbon monoxide>6ppm)
willing to be randomized
English speaking

Exclusion:

unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, substance abuse, or dementia
in the immediate (within 2 weeks) post myocardial infarction period
serious arrhythmias
unstable angina pectoris
hemodynamically or electrically unstable
currently taking part in any other tobacco treatment program or using cessation medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline, in another drug study).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03927989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.